双阶段药物输送微球通过凝固增强的血管封闭扩大瘤饥饿
Kexin Wen1, Yingjie Ren1, Junjun Huang1
1Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medicine Sciences, Jinan, Shandong, 250117, P. R. China.
Small (Weinheim an der Bergstrasse, Germany)
|September 24, 2025
概括
这项研究开发了响应pH的微球,以增强瘤饥饿疗法. 微球共同提供诱导血液凝固的药物,显著提高抗瘤功效并减少转移.
科学领域:
- 生物材料科学 生物材料科学
- 癌症治疗 癌症治疗
- 药物输送系统 药物输送系统
背景情况:
- 瘤饥饿疗法面临来自不完全血管封闭和瘤代谢适应的挑战.
- 有效的营养剥夺需要对瘤血管系统进行强有力的持续破坏.
- 需要新的策略来克服瘤饥饿治疗中的抵抗机制.
研究的目的:
- 开发一个pH响应的微球系统,用于协同的瘤饥饿疗法.
- 为了同时提供一种血管干扰剂和一种促凝剂,以增强瘤血管封闭.
- 调查开发系统的治疗疗效和抗转移潜力.
主要方法:
- 制造多孔的多乳-co-甘油酸 (PLGA) 微球,嵌入具有pH响应的碳酸 (CaCO3) 纳米颗粒.
- 在微球中同时封装5,6-二甲基甘-4-酸 (DMXAA) 和血栓.
- 在体外评估由酸性瘤微环境触发的连续药物释放.
- 在B16F10黑色素瘤和4T1乳腺癌小鼠模型中的治疗功效的体内评估.
主要成果:
- 工程微球显示了pH响应的DMXAA和血栓蛋白的顺序释放.
- 加入CaCO3增强了药物负载,并为凝固提供了Ca2+离子.
- 在B16F10模型中观察到显著的瘤生长减缓和血管血栓形成.
- 在4T1模型中,有效地缓解了原发性瘤生长和肺转移.
结论:
- 开发的多功能微球为协同瘤饥饿疗法提供了一个有前途的战略.
- 连续的药物释放和诱导的血管内凝血增强了抗瘤功效.
- 该系统显示了对初级瘤控制和减少转移性传播的潜力.
更多相关视频
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
16.4K
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.5K
相关概念视频
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
